Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.

Sesmilo G, Fairfield WP, Katznelson L, Pulaski K, Freda PU, Bonert V, Dimaraki E, Stavrou S, Vance ML, Hayden D, Klibanski A

The Journal of clinical endocrinology and metabolism1 Apr 2002Cited by 83 (Europe PMC)

PMID11932303DOI10.1210/jcem.87.4.8364PepBankPUB-11932303

Source link PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In acromegaly patients, pegvisomant showed no significant placebo differences in IL-6, homocysteine, glucose, insulin, triglyceride, total cholesterol, LDL cholesterol or HDL cholesterol.
In plain wordsIn acromegaly patients, pegvisomant did not significantly change the listed inflammatory and metabolic markers compared with placebo.
Peptide
Pegvisomant
Outcome
No significant changeOther inflammatory and metabolic markers
Study
n = 48
Comparator
Placebo
Outcome group
Cardiovascular Risk Markers · Cardiovascular
Studied dose
10, 15 or 20 mg daily · 12 weeksAs given in this study (human).
Source sentences
Summary
There were no significant differences in IL-6, homocysteine, glucose, insulin, triglyceride, total cholesterol, LDL cholesterol and HDL cholesterol levels.
2 context sentences(design, population, supporting numbers)
Summary · context
After baseline evaluation, patients with acromegaly were randomized to placebo (n = 14), 10 mg (n = 12), 15 mg (n = 10), or 20 mg (n = 12) daily pegvisomant for 12 wk.
Summary · context
The study consisted of 3 parts: a cross-sectional study, a prospective randomized 12-wk placebo-controlled study, and a longitudinal open-label study of up to 18 months of pegvisomant treatment.
Report a problemFND-1193230302
02HumanRandomized controlled trialEfficacy outcome
In patients with acromegaly, CRP increased with pegvisomant 20 mg compared with placebo (13.7 +/- 3.6 versus 0.5 +/- 3.3 mg/liter, P = 0.010).
In plain wordsIn patients with acromegaly, pegvisomant 20 mg increased CRP more than placebo.
Peptide
Pegvisomant
Outcome
IncreaseCRP versus placebo
Study
n = 26
Comparator
Placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
20 mg daily · 12 weeksAs given in this study (human).
Measurements
CRP
13.7 mg/liter
pegvisomant 20 mg
CRP
0.5 mg/liter
placebo
Source sentences
Summary
In the placebo-controlled study, CRP increased in patients treated with 20 mg pegvisomant, compared with placebo (mean +/- SEM, 13.7 +/- 3.6 vs. 0.5 +/- 3.3 mg/liter; P = 0.010).
2 context sentences(design, population, supporting numbers)
Summary · context
After baseline evaluation, patients with acromegaly were randomized to placebo (n = 14), 10 mg (n = 12), 15 mg (n = 10), or 20 mg (n = 12) daily pegvisomant for 12 wk.
Summary · context
The study consisted of 3 parts: a cross-sectional study, a prospective randomized 12-wk placebo-controlled study, and a longitudinal open-label study of up to 18 months of pegvisomant treatment.
Report a problemFND-1193230301
03HumanNon-randomized trialEfficacy outcome
In acromegaly patients during open-label pegvisomant treatment, CRP increased by 2.0 +/- 0.5 mg/liter (P = 0.0002).
In plain wordsIn acromegaly patients, CRP increased compared with baseline during open-label pegvisomant treatment.
Peptide
Pegvisomant
Outcome
IncreaseLongitudinal CRP change
Study
n: not reported in source
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
At least 10 mg daily, adjusted to normalize IGF-I · Median 15.6 monthsAs given in this study (human).
Measurements
CRP change
2 mg/liter
longitudinal study
Source sentences
Summary
In the longitudinal open-label study (median duration, 15.6 months), CRP increased by 2.0 +/- 0.5 mg/liter (P = 0.0002).
2 context sentences(design, population, supporting numbers)
Summary · context
Subsequently, all patients received at least 10 mg pegvisomant daily for up to 18 months, with dose adjustments to achieve a normal IGF-I level.
Summary · context
The study consisted of 3 parts: a cross-sectional study, a prospective randomized 12-wk placebo-controlled study, and a longitudinal open-label study of up to 18 months of pegvisomant treatment.
Report a problemFND-1193230303
04HumanNon-randomized trialEfficacy outcome
In acromegaly patients during open-label pegvisomant treatment, total cholesterol increased by 0.22 +/- 0.11 mM (P = 0.050).
In plain wordsIn acromegaly patients, total cholesterol increased compared with baseline during open-label pegvisomant treatment.
Peptide
Pegvisomant
Outcome
IncreaseLongitudinal total cholesterol change
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
At least 10 mg daily, adjusted to normalize IGF-I · Median 15.6 monthsAs given in this study (human).
Measurements
Total cholesterol change
0.22 mM
longitudinal study
Source sentences
Summary
Total cholesterol and triglycerides increased (0.22 +/- 0.11 mM, P = 0.050; and 0.25 +/- 0.09 mM, P = 0.007, respectively), whereas lipoprotein(a) decreased (-70 +/- 33 mg/liter, P = 0.039).
3 context sentences(design, population, supporting numbers)
Summary · context
In the longitudinal open-label study (median duration, 15.6 months), CRP increased by 2.0 +/- 0.5 mg/liter (P = 0.0002).
Summary · context
Subsequently, all patients received at least 10 mg pegvisomant daily for up to 18 months, with dose adjustments to achieve a normal IGF-I level.
Summary · context
The study consisted of 3 parts: a cross-sectional study, a prospective randomized 12-wk placebo-controlled study, and a longitudinal open-label study of up to 18 months of pegvisomant treatment.
Report a problemFND-1193230304
05HumanNon-randomized trialEfficacy outcome
In acromegaly patients during open-label pegvisomant treatment, triglycerides increased by 0.25 +/- 0.09 mM (P = 0.007).
In plain wordsIn acromegaly patients, triglycerides increased compared with baseline during open-label pegvisomant treatment.
Peptide
Pegvisomant
Outcome
IncreaseLongitudinal triglyceride change
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
At least 10 mg daily, adjusted to normalize IGF-I · Median 15.6 monthsAs given in this study (human).
Measurements
Triglyceride change
0.25 mM
longitudinal study
Source sentences
Summary
Total cholesterol and triglycerides increased (0.22 +/- 0.11 mM, P = 0.050; and 0.25 +/- 0.09 mM, P = 0.007, respectively), whereas lipoprotein(a) decreased (-70 +/- 33 mg/liter, P = 0.039).
3 context sentences(design, population, supporting numbers)
Summary · context
In the longitudinal open-label study (median duration, 15.6 months), CRP increased by 2.0 +/- 0.5 mg/liter (P = 0.0002).
Summary · context
Subsequently, all patients received at least 10 mg pegvisomant daily for up to 18 months, with dose adjustments to achieve a normal IGF-I level.
Summary · context
The study consisted of 3 parts: a cross-sectional study, a prospective randomized 12-wk placebo-controlled study, and a longitudinal open-label study of up to 18 months of pegvisomant treatment.
Report a problemFND-1193230305
06HumanNon-randomized trialEfficacy outcome
In acromegaly patients during open-label pegvisomant treatment, lipoprotein(a) decreased by 70 +/- 33 mg/liter (P = 0.039).
In plain wordsIn acromegaly patients, lipoprotein(a) decreased compared with baseline during open-label pegvisomant treatment.
Peptide
Pegvisomant
Outcome
DecreaseLongitudinal lipoprotein(a) change
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
At least 10 mg daily, adjusted to normalize IGF-I · Median 15.6 monthsAs given in this study (human).
Measurements
Lipoprotein(a) change
−70 mg/liter
longitudinal study
Source sentences
Summary
Total cholesterol and triglycerides increased (0.22 +/- 0.11 mM, P = 0.050; and 0.25 +/- 0.09 mM, P = 0.007, respectively), whereas lipoprotein(a) decreased (-70 +/- 33 mg/liter, P = 0.039).
3 context sentences(design, population, supporting numbers)
Summary · context
In the longitudinal open-label study (median duration, 15.6 months), CRP increased by 2.0 +/- 0.5 mg/liter (P = 0.0002).
Summary · context
Subsequently, all patients received at least 10 mg pegvisomant daily for up to 18 months, with dose adjustments to achieve a normal IGF-I level.
Summary · context
The study consisted of 3 parts: a cross-sectional study, a prospective randomized 12-wk placebo-controlled study, and a longitudinal open-label study of up to 18 months of pegvisomant treatment.
Report a problemFND-1193230306
07HumanNon-randomized trialEfficacy outcome
In acromegaly patients during open-label pegvisomant treatment, glucose, insulin, homocysteine, HDL cholesterol and IL-6 did not change.
In plain wordsIn acromegaly patients, the listed metabolic and inflammatory markers did not change from baseline during open-label pegvisomant treatment.
Peptide
Pegvisomant
Outcome
No significant changeOther longitudinal metabolic and inflammatory markers
Study
n: not reported in source
Outcome group
Cardiovascular Risk Markers · Cardiovascular
Studied dose
At least 10 mg daily, adjusted to normalize IGF-I · Median 15.6 monthsAs given in this study (human).
Source sentences
Summary
Glucose, insulin, homocysteine, HDL cholesterol, and IL-6 did not change.
3 context sentences(design, population, supporting numbers)
Summary · context
In the longitudinal open-label study (median duration, 15.6 months), CRP increased by 2.0 +/- 0.5 mg/liter (P = 0.0002).
Summary · context
Subsequently, all patients received at least 10 mg pegvisomant daily for up to 18 months, with dose adjustments to achieve a normal IGF-I level.
Summary · context
The study consisted of 3 parts: a cross-sectional study, a prospective randomized 12-wk placebo-controlled study, and a longitudinal open-label study of up to 18 months of pegvisomant treatment.
Report a problemFND-1193230307

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:34 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.